Single dose repaglinide has no acute effect on platelet aggregation in newly diagnosed type 2 diabetes mellitus patients

Tip 2 diyabetes mellitus platelet aşırı reaktivitesi, endotel disfonksiyonu ve kardiyovasküler komplikasyon riskinin artmasına neden olur. Bunun yanı sıra oral antidiyabetikler platelet fonksiyonlarını etkilemektedir. Bu çalışmanın amacı yeni bir oral antidiyabetik olan repaglinid’in tek doz uygulamasının platelet fonksiyonları üzerine etkisini belirlemektir. Eşlik eden herhangi bir hastalığı olmayan, makrovasküler diyabetik komplikasyonu olmayan ve herhangi bir tedavi kullanmayan yeni tanı konulmuş 37 tip 2 diyabet hastası çalışmaya alındı. Her ana öğünden once 0,5-2 mg oral repaglinid tüm katılımcılara verildi ve standardize edilmiş yemek öncesi ve 1 saat sonrasında platelet aggregasyonu çalışıldı. Tek doz repaglinid uygulamasından önce ve sonra platelet agregasyon test sonuçları arasında istatistiksel olarak önemli fark yoktu. Çalışmamızın sonuçları tek doz repaglinid uygulamasının tip 2 diyabetik hastaların akut fazında platelet agregasyonu üzerine etkisi olmadığını göstermektedir.

Yeni tanı konulmuş tip 2 diyabetes mellituslu has-talarda tek doz repaglinid’in platelet agregasyonu üzerinde akut etkisi yoktur

Type 2 diabetes mellitus (T2DM) is associated with platelet hyperreactivity, endothelial dysfunction and an increased risk of cardiovascular complications. Besides, oral antidiabetic agents alter the platelet functions. The aim of this study was to assess the effect of single dose repaglinide, a novel oral antidiabetic, on platelet functions. Thirty-seven newly diagnosed type 2 diabetic patients without any concomitant disease, macrovascular diabetic complications and free of any treatment were enrolled to the study. Oral repaglinide 0.5-2 mg was administered to all participants before each principal meal and platelet aggregation was studied before and one hour after a standardized meal. There was no statistically significant difference in platelet aggregation test results before and after single dose repaglinide administration. Results of our study imply that a single dose of repaglinide has no effect on platelet aggregation in the acute phase of type 2 diabetic patients.

___

  • 1. Yngen M, Ostenson CG, Hjemdahl P, Wallen NH. Meal-induced platelet activation in type 2 diabetes mellitus: effects of treatment with repaglinide and glibenclamide. Diabetes UK. Diabetic Medicine 2005;23: 134-40.
  • 2. Khanolkar MP, Morris RH, Thomas AW, Bolusani H, Roberts AW, Geen J, et al. Rosiglitazone produces a greater reduction in circulating platelet activity compared with gliclazide in patients with type 2 diabetes mellitus-an effect probably mediated by direct platelet PPARgamma activation. Atherosclerosis 2008;197: 718-24.
  • 3. Formoso G, De Filippis EA, Michetti N, Di Fulvio P, Pandolfi A, Bucciarelli T, et al. Decreased in vivo oxidative stress and decreased platelet activation following metformin treatment in newly diagnosed type 2 diabetic subjects. Diabetes Metab Res Rev 2008;24: 231-7.
  • 4. Owens DR. Repaglinide: a new short-acting insulinotropic agent for the treatment of Type 2 diabetes. Eurpean Journal of Clinical Investigation 1999;29: 30-7.
  • 5. World Health Organization: Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO Consultation. Part 1: diagnosis and classification of diabetes mellitus. 1999 [http:// whqlibdoc.who.int/hq/1999/WHO_NCD_NCS_99.2.pdf].Geneva,Switzerland: World Health Organization.
  • 6. Sirridge MS, Shannon R, editors. Laboratory Evaluation of Haemostasis and Thrombosis. 3rd ed. Philadelphia: Lea and Febiger 1983; p: 86-98.
  • 7. De Fronzo RA. Pharmacologic therapy for Type 2 Diabetes Mellitus. Ann Intern Med 1999;131: 281-303.
  • 8. Nattrass M. Repaglinide: a novel oral antidiabetic agent. Hospital Medicine 2000;61: 112-5.
  • 9. Gresele P, Guglielmini G, De Angelis M, Ciferri S, Cifetta M, Falcinelli E, et al. Acute, short-therm hyperglycemia enhances shear stresinduced platelet activation in patients with type 2 diabetes mellitus. J Am Coll Cardiol 2003;41: 1013-20.
  • 10. Ross R. Atherosclerosis an inflammatory disease. N Engl J Med 1999;340: 115-26.
  • 11. Gryglewski RJ, Botting RM, Vane JR. Mediators produced by the endothelial cell. Hypertension 1988;12: 530-48.
  • 12. Gawaz M, Langer H, May AE. Platelets in inflammation and atherogenesis. J Clin Invest 2005;115: 3378-84.
  • 13. Colwell JA. Antiplatelet agents for the prevention of cardiovascular disease in diabetes mellitus. Am J Cardiovasc Drugs 2004;4: 87-106.
  • 14. Vinik AI, Erbas T, Park TS, Nolan R, Pittenger GL. Platelet dysfunction in type 2 diabetes. Diabetes Care 2001;24: 1476-85.
  • 15. Ashby B, Daniel JL, Smith JB. Mechanisms of platelet activation and inhibition. Hematol Oncol Clin North Am 1990;4: 1-26.
  • 16. Akai T, Naka K, Okuda K, Takemura T, Fujii S. Decreased sensitivity of platelets to prostacyclin in patients with diabetes mellitus. Horm Metab Res 1983;15: 523-6.
  • 17. Nolan RD, Platt KH, Loose PG. The resistance to nitric oxide inhibition of platelet aggregation is due to decreased phosphorylation of rap 1B in platelets of NIDDM compared with control subjects. Diabetes 1994; 43: 101A.
  • 18. Hishinuma T, Yamazaki T, Mizugaki M. Troglitazone has a reducing effect on thromboxane production. Prostaglandins Other Lipid Mediat 2000;62: 135-43.
  • 19. Ishizuka T, Itaya S, Wada H, Ishizawa M, Kimura M, Kajita K, et al. Differential effect of the antidiabetic thiazolidinediones troglitazone and pioglitazone on human platelet aggregation mechanism. Diabetes 1998;47: 1494-500.
  • 20. Owens DR. Repaglinide –Prandial glucose regulator. A new class of oral antidiabetic drugs. Diabetic Medicine 1998;15: 528-36.
Yeni Tıp Dergisi-Cover
  • ISSN: 1300-2317
  • Yayın Aralığı: Yılda 4 Sayı
  • Başlangıç: 2018
  • Yayıncı: -
Sayıdaki Diğer Makaleler

Hemşirelik öğrencilerinin engellilere yönelik tutumlarının belirlenmesi

Hatice Yıldırım SARI, Murat BEKTAŞ, Saliha ALTIPARMAK

Postmenopozal hormon tedavisi kardiyovasküler hastalık riskini azaltıyor mu?

Nilgün Öztürk TURHAN, Serap SİMAVLI, İlknur İnegöl GÜMÜŞ

The effects of caffeic acid phenethyl ester (CAPE) on acetic acid induced colitis in rats

Elife ERARSLAN, Cansel TÜRKAY, Burak UZ, Arif KAYA, Cemile KOCA, Reyhan BAYRAK, Özlem ALICI

Adolescent pregnancies: Maternal and fetal outcomes

ZEHRA CANDAN İLTEMİR DUVAN, Nilgün Öztürk TURHAN, Yüksel ONARAN, İlknur İnegöl GÜMÜŞ, HİLAL USLU YUVACI, Elif GÖZDEMİR

Sol omuzda nodüler melanom, amelanotik melanom ve yüzeyel yayılan malign melanom birlikteliği olan bir olgu sunumu

Zeynep TÜRKŞEN, Ömer Faruk TANER, Ayla TEZER, AYŞE SERAP KARADAĞ, Fatih TEKİN

L-asparaginaz allerjisi sürekli adrenalin infüzyonu eşliğinde yapılan desensitizasyonla aşılabilir mi?

Semra KARA, NURULLAH ÇELİK, Ömer CEVİT, Hayri B. TOKSOY

Single dose repaglinide has no acute effect on platelet aggregation in newly diagnosed type 2 diabetes mellitus patients

Engin Deniz GÖK, Oral NEVRUZ, Mehmet YOKUŞOĞLU, Cengiz BEYAN, Mahmut YAZICI, Mustafa KUTLU

Posterior sirkülasyon infarktında baziler arter dolikoektazisinin MRG ile değerlendirilmesi

Bahri KEYİK, Gököen Çoban ŞAHİN, Bahar YANIK, Baki HEKİMOĞLU

"Değişik özür seviyesindeki serebral palsili çocukların annelerinin depresyon düzeyleri farklı mıdır?"

Akmer MUTLU, PELİN PİŞTAV AKMEŞE, Mintaze Kerem GÜNEL

Proteomik

SEVİL KURBAN, İdris MEHMETOĞLU